Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.57 | N/A | +3.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.57 | N/A | +3.64% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future prospects. They reiterated their commitment to innovation and addressing market dynamics.
Management highlighted ongoing efforts in research and development.
They emphasized the importance of maintaining strong product pipelines.
There was a focus on long-term growth despite current market challenges.
Pfizer's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 2.57%, likely due to investor concerns about revenue visibility and lack of guidance. The cautious tone from management may have contributed to the stock's decline as investors weigh future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 2, 2014